Supplementary Material for: Adebrelimab Combined with Chemotherapy for Esophageal Neuroendocrine Carcinoma：A Case Report

Introduction: Esophageal neuroendocrine carcinoma is an extremely rare type of esophageal cancer. Due to the limited number of cases, there are no established diagnostic and treatment guidelines.Case Presentation: A 60-year-old male presented with dysphagia and was subsequently diagnosed with large cell neuroendocrine carcinoma of the esophagus. He received four cycles of treatment with Adebrelimab combined with etoposide and carboplatin, which resulted in significant tumor shrinkage.Conclusion: Esophageal neuroendocrine carcinoma is a highly malignant tumor with a high mortality rate. A better understanding of its diagnosis and treatment strategies may contribute to favorable trends in patient outcomes, while its actual effect on long-term prognosis remains to be validated with extended follow-up.